Blog

Oct 26, 2024, 18:14

BeiGene’s BTK Inhibitor was successfully launched in Ethiopia for CLL patients at Black Lion Hospital

John V. Oyler, Founder, Chairman & CEO at BeiGene, shared a post on LinkedIn:

“This week, I received an inspiring message from the The Max Foundation, highlighting a pivotal milestone for BeiGene. Our BTK Inhibitor was successfully launched in Ethiopia for CLL patients at Black Lion Hospital.

The message from the doctor on the ground conveyed the profound impact: patients are now filled with excitement and hope, while the hematology team is both motivated and relieved to have access to a first-line therapy that would have been unattainable for decades.

At BeiGene, we are committed to putting patients at the heart of everything we do. Their courage and resilience inspire us daily, driving our relentless pursuit to expand access to life-changing therapies worldwide.”

BeiGene Black Lion Hospital BTK inhibitor cancer cancer awareness cancer care Ethiopia fight against cancer Global fight against cancer John V. Oyler OncoDaily Oncology The Max Foundation

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity